Lymphocyte-predominant Hodgkin's lymphoma in children: Therapeutic abstention after initial lymph node resection - A study of the French Society of Pediatric Oncology

Journal of Clinical Oncology

Volumn 21, Issue 15, 2003, Pages 2948-2952

  Pellegrino, B ^b   Terrier Lacombe, M J ^b   Oberlin, O ^b   Leblanc, T ^b   Perel, Y ^b   Bertrand, Y ^b   Beard, C ^b   Edan, C ^b   Schmitt, C ^b   Plantaz, D ^b   Pacquement, H ^b   Vannier, J P ^b   Lambilliote, C ^b   Couillault, G ^b   Babin Boilletot, A ^b   Thuret, I ^b   Demeocq, F ^b   Leverger, G ^b   Delsol, G ^b   Landman Parker, Judith ^a  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LYMPHADENECTOMY; LYMPHOCYTE; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; CHILD; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSPECTIVE STUDY; REMISSION; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0042887526     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.079     Document Type: Article

References (25)

1. Poppema S: Lymphocyte predominance Hodgkin's disease. Semin Diagn Pathol 9:257-264, 1992
2. Bodis S, Kraus MD, Pinkus G, et al: Clinical presentation and outcome in lymphocyte predominant Hodgkin's disease. J Clin Oncol 15:3060-3066, 1997
3. Karayalcin G, Behm FG, Gieser PW, et al: Lymphocyte predominant Hodgkin disease: Clinico-pathologic features and results of treatment-The Pediatric Oncology Group Experience. Med Pediatr Oncol 29:519-525, 1997
4. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
5. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
6. Anagnostopoulos I, Hansmann ML, Franssila, et al: European Task Force on Lymphoma Project on lymphocyte predominance Hodgkin disease: Histologie and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96:1889-1899, 2001
7. Orlandi E, Lazzarino M, Brusamolino E, et al: Nodular lymphocyte predominance Hodgkin's disease: Long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma 26:359-368, 1997
8. Diehl V, Sextro M, Franklin J, et al: Clinical presentation, course and prognostic factors in lymphocyte predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on lymphocyte-predominant Hodgkin's disease report. J Clin Oncol 17:776-790, 1999
9. Pappa VI, Norton AJ, Gupta RK, et al: Nodular type of lymphocyte predominant Hodgkin's disease, a clinical study of 50 cases. Ann Oncol 6:559-565, 1995
10. Russell KJ, Hoppe RT, Burns BF, et al: Lymphocyte predominant Hodgkin's disease: Clinical presentation and result of treatment. Radiother Oncol 1:197-205, 1989
11. Regula DP, Hoppe RT, Weiss LM: Nodular and diffuse types of lymphocyte Hodgkin's disease. N Engl J Med 318:214-219, 1988
12. Trudel MA, Krikorian JG, Neimann RS: Lymphocyte predominant Hodgkin's disease: A clinicopathologic reassessment. Cancer 59:99-106, 1987
13. Miettinen M, Franssila KO, Saxen E: Hodgkin's disease, lymphocytic predominance nodular: Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 54:2293-2300, 1983
14. Meignin V, Briere J, Brice P, et al: Maladie de Hodgkin à predominance lymphocytaire nodulaire de type I (paragranulome de Poppema-Lennert): une entité anatomo-clinique. Ann Pathol 20:19-24, 2000
15. Ha CS, Kavadi V, Dimopoulos MA, et al: Hodgkin's disease with lymphocyte predominance: Long-term results based on current histopathologic criteria. Int J Radiat Oncol Biol Phys 43:329-334, 1999
16. Divine M, Brice P, Bastion Y, et al: Indolent relapsing pattern in nodular lymphocyte-predominance Hodgkin's disease: The GELA experience in a series of 69 patients-6th International Conference on Malignant Lymphoma, Lugano 1996. Ann Oncol 7:S1-S230, 1996 (suppl 3)
17. Mason D, Banks P, Chan J, et al: Nodular lymphocyte predominant Hodgkin's disease: A distinct clinicopathologic entity. Am J Surg Pathol 18:526-530, 1994
18. Oberlin O, Leverger G, Pacquement H, et al: Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol 10:1602-1608, 1992
19. Landman-Parker J, Leblanc T, Pacquement H, et al: Localized childhood Hodgkin's disease: Response-adapted treatment by chemotherapy regimen with etoposide, bleomycin, vinblastine, and prednisone before low dose radiation therapy-Results of the study by the French Society of Pediatric Oncology. J Clin Oncol 18:1500-1507, 2000
20. Timens W, Visser L, Poppema S: Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma. Lab Invest 54:457-461, 1986
21. Chittal S, Alard C, Rossi JF: Further phenotypic evidence that nodular lymphocyte predominant Hodgkin's disease is a large B cell lymphoma in evolution. Am J Surg Pathol 14:1024-1035, 1990
22. Marafioti T, Hummel M, Anagnostopoulos I, et al: Origin of nodular lymphocyte predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 33:453-458, 1997
23. Green DM, Maurice AH, Barcos P, et al: Second malignant neoplasms after treatment for Hodgkin's disease in childhood and adolescence. J Clin Oncol 18:1492-1499, 2000
24. Keilholz U, Szelenyi H, Siehl J, et al: Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD20 monoclonal antibody) and interleukin 2. Leuk Lymphoma 35:641-642, 1999
25. Schulz H, Rehwald U, Reiser M et al: The monoclonal antibody rituximab is well tolerated and extremely effective in the treatment of relapsed CD20-positive Hodgkin's lymphoma: An update-8th International Conference on Malignant Lymphoma, Lugano 2002. Ann Oncol 13:63, 2002 (suppl 2, abstr 210)